Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.

Daniela SieghartClaudia A HanaCaroline DürrschmidLeonhard X HeinzHelmuth HaslacherMarkus ZlesakGiulia PicciniAlessandro ManentiEmanuele MontomoliAnselm JordaClemens FedrizziTimothy HasenoehrlAndrej ZdravkovicKarolina AnderleUrsula WiedermannSusanne DrapalikHelmut SteinbrecherFelix BergmannChrista FirbasGalateja JordakievaBarbara WagnerMargherita LeonardiGiulio PierleoniMatilde BalliniLinda BenincasaSerena MarchiClaudia TrombettaThomas PerkmannRichard CrevennaMarkus ZeitlingerMichael BonelliDaniel AletahaHelga Radner

Published in: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2024)

Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy.

Keyphrases

clinical trial
coronavirus disease
sars cov
randomized controlled trial
study protocol
binding protein
double blind
phase ii